PEG-FFI

PreclinicalSmall molecule

NNingbo No. 1 Hospital

PEG-FFI is one of 7 small molecule programs targeting MPR. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MPRCompleted

MPRPreclinical

Completed

Competition

Competitive Landscape

11 competitors in MPR

#DrugCompanyPhaseTrials

Lioresal

Novartis

Phase 3

1 2

Glycerin

CCalm Water Therapeutics LLC

Phase 3

1 3

Fragmin

Pfizer

Preclinical

1 4

Agenerase

GGlaxo Dba Glaxosmithkline

Preclinical

3 5

ECT-001-CB

EExCellThera inc.

Phase 2

1 6

Urine Collection

CCHU de Reims

Preclinical

1 7

PEG-FFI

NNingbo No. 1 Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

MPR1 trial

FFI and PR Could Improve Bowel Cleansing.

Completed·NNingbo No. 1 Hospital·N/A·NCT04605432·320 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PEG-FFI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEG-FFI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEG-FFI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ningbo No. 1 Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNingbo No. 1 Hospital

PEG-FFI

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

MPR1 trial

References

Drug Info

Quick Facts

Related News